Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 15.5% in the year so far compared with the industry’s decline of 6.3%. The stock has underperformed the sector and the S&P 500 Index during ...

Biotech companies are making monumental strides in cancer treatment, leveraging cutting-edge technologies to redefine the ...

Check the time stamp on this data. Updated AI-Generated Signals for Regeneron Pharmaceuticals Inc. (REGN) available here: ...

Positive clinical trial results for Merck & Co's experimental antiviral COVID-19 pill reverberated through the health care sector on Friday, sending the drugmaker's stock price soaring while ...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.

If an investor was to purchase shares of REGN stock at the current price level of $756.89/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock ...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.

REGN dropped to an RSI of about 10 ... the outcome of the DOJ case and the amount of the potential fine. The stock price may also have limited upside until a decision is made in the courts.

BofA reinstated coverage of Regeneron (REGN) with an Underperform rating and $565 price target The firm calls Regeneron a “high-quality ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.